2,040 results match your criteria Expert Review of Vaccines[Journal]


Deciphering protective immunity against tuberculosis: implications for vaccine development.

Expert Rev Vaccines 2019 Feb 22. Epub 2019 Feb 22.

a Tuberculosis Research Program Centenary Institute , The University of Sydney , Camperdown , NSW , Australia .

Introduction: The development of more effective tuberculosis (TB) vaccines is essential for the global control of TB. In the last decade, there have been major advances in the field, but an important hindrance remains the lack of correlates of protection against TB. This requires each vaccine candidate to undergo clinical efficacy trials based on data from animal protection studies, but the results from animal models do not necessarily predict efficacy in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1585246DOI Listing
February 2019

Recombinant influenza A viruses as vaccine vectors.

Expert Rev Vaccines 2019 Feb 19. Epub 2019 Feb 19.

a University of Veterinary Medicine (TiHo), Research Center for Emerging Infections and Zoonoses (RIZ) , Bünteweg 17, 30559 Hannover , Germany.

Introduction: Various viruses, including poxviruses, adenoviruses and vesicular stomatitis virus, have been considered as vaccine vectors for the delivery of antigens of interest in the development of vaccines against newly emerging pathogens. Areas covered: Here, we review results that have been obtained with influenza A viruses (IAV) as vaccine vectors. With the advent of reverse genetics technology, IAV-based recombinant vaccine candidates have been constructed that induce protective immunity to a variety of different pathogens of interest, including West Nile virus, Plasmodium falciparum and respiratory syncytial virus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1582338DOI Listing
February 2019

Experimental models used in evaluating anti-tuberculosis vaccines: the latest advances in the field.

Expert Rev Vaccines 2019 Feb 16. Epub 2019 Feb 16.

b Basic Sciences Department , School of Medicine and Health Sciences, Universidad del Rosario , Carrera 24 No. 63C-69, Bogotá , Colombia.

Introduction: Tuberculosis is an infectious disease which is caused by bacilli from the M. tuberculosis complex. The Mycobacterium bovis Bacillus Calmette-Guérin vaccine is currently available as a prophylactic tool for preventing the disease; it has been shown to be efficient in preventing disseminated forms of tuberculosis during early ages, however, its efficiency is limited in areas where individuals have had prior exposure to environmental mycobacteria and its efficacy decreases with a host's age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1583558DOI Listing
February 2019

HPV vaccination in Japan: what is happening in Japan?

Expert Rev Vaccines 2019 Feb 15:1-3. Epub 2019 Feb 15.

a Department of Gynecology, Tama-Hokubu Medical Center , Tokyo Metropolitan Health and Medical Treatment Corporation , Higashimurayama, Tokyo , Japan.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1584040DOI Listing
February 2019
2 Reads

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States.

Expert Rev Vaccines 2019 Feb 13. Epub 2019 Feb 13.

a Department of Health Policy , Vanderbilt University , Nashville , Tennessee , USA.

Introduction: Pneumonia is one of the leading causes of morbidity and mortality among children and older adults. Pneumococcal conjugate vaccines (PCVs) were introduced into the US routine infant vaccination schedule leading to substantial reductions of invasive pneumococcal diseases (IPD). PCVs introduction also led to reductions in all-cause pneumonia among US children, though the indirect impact of PCVs on pneumonia in adults is difficult to quantify, especially due to the recent US recommendation for direct PCV use in older adults. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1582337DOI Listing
February 2019

Optimizing the timing of 4CMenB vaccination in adolescents and young adults based on immune persistence and booster response data.

Expert Rev Vaccines 2019 Feb 11. Epub 2019 Feb 11.

d GSK Vaccines GmbH , Emil-von-Behring-Strasse 76, 35041 Marburg , Germany .

Introduction: Meningococcal disease has an incidence peak spread over several years during adolescence and young adulthood in the United States. Meningococcal serogroup B (MenB) vaccines have been introduced relatively recently and may help protect individuals in these age groups. Currently there is insufficient long-term experience to determine the duration of disease protection after any MenB vaccine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1580579DOI Listing
February 2019

Post-hoc analysis from phase iii trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.

Expert Rev Vaccines 2019 Feb 11. Epub 2019 Feb 11.

c GSK , Rixensart , Belgium.

Background: Substantial heterogeneity has been reported in efficacy against high-grade cervical intraepithelial neoplasia (CIN) irrespective of type in phase III results for bivalent and quadrivalent human papillomavirus virus (HPV) vaccines (AS04-HPV and qHPV). Real-world data recently confirmed very high overall impact of AS04-HPV, supporting the validity of the observed heterogeneity. To explore the reasons for heterogeneous efficacy, we assessed vaccine impact on high-grade lesions not caused by vaccine types. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1579647DOI Listing
February 2019
1 Read

The prevention of severe pertussis and pertussis deaths in young infants.

Authors:
James D Cherry

Expert Rev Vaccines 2019 Feb 8:1-4. Epub 2019 Feb 8.

a Department of Pediatrics , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.

Introduction: Today, in the developed world, virtually all deaths due to Bordetella pertussis illnesses occur in young infants. Areas Covered: Pertussis in young infants is characterized by an afebrile cough illness with coryza, apnea, seizures, cyanosis, and emesis. Severe illness is associated with high leukocyte and lymphocyte counts, rapid respiratory and cardiac rates and pneumonia. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1581065DOI Listing
February 2019
4 Reads

Human challenge models: tools to accelerate the development of malaria vaccines.

Expert Rev Vaccines 2019 Feb 7. Epub 2019 Feb 7.

a Centre for Molecular Therapeutics , Australian Institute of Tropical Health and Medicine, James Cook University , Cairns QLD 4878 , Australia.

Introduction: Malaria challenge models, where healthy human volunteers are intentionally infected with Plasmodium species parasites under controlled conditions, can be undertaken in several well-defined ways. These challenge models enable evaluation of the kinetics of parasite growth and clearance, host-pathogen interactions and the host immune response. They can facilitate discovery of candidate diagnostic biomarkers and novel vaccine targets. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1580577DOI Listing
February 2019
6 Reads

Immunological basis for enhanced immunity of nanoparticle vaccines.

Expert Rev Vaccines 2019 Feb 1:1-12. Epub 2019 Feb 1.

a Department of Microbiology and Immunology , University of Melbourne, at The Peter Doherty Institute for Infection and Immunity , Melbourne , Australia.

Introduction: Immunization has been a remarkably successful public health intervention; however, new approaches to vaccine design are essential to counter existing and emerging infectious diseases which have defied traditional vaccination efforts to date. Nanoparticles (ordered structures with dimensions in the range of 1-1000 nm) have great potential to supplement traditional vaccines based upon pathogen subunits, or killed or attenuated microorganisms, as exemplified by the successful licensure of virus-like particle vaccines for human papillomavirus and hepatitis B. However, the immunological mechanisms that underpin the potent immunity of nanoparticle vaccines are poorly defined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1578216DOI Listing
February 2019
1 Read

The role of systems biology approaches in determining molecular signatures for the development of more effective vaccines.

Expert Rev Vaccines 2019 Jan 31:1-15. Epub 2019 Jan 31.

a Mayo Vaccine Research Group , Mayo Clinic , Rochester , MN , USA.

Introduction: Emerging infectious diseases are a major threat to public health, and while vaccines have proven to be one of the most effective preventive measures for infectious diseases, we still do not have safe and effective vaccines against many human pathogens, and emerging diseases continually pose new threats. The purpose of this review is to discuss how the creation of vaccines for these new threats has been hindered by limitations in the current approach to vaccine development. Recent advances in high-throughput technologies have enabled scientists to apply systems biology approaches to collect and integrate increasingly large datasets that capture comprehensive biological changes induced by vaccines, and then decipher the complex immune response to those vaccines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1575208DOI Listing
January 2019

Introducing new vaccines in low- and middle-income countries: challenges and approaches.

Expert Rev Vaccines 2019 Feb 11;18(2):119-131. Epub 2019 Feb 11.

a Research and Development , GSK , Wavre , Belgium.

Introduction: The number of new vaccine introductions (NVIs) in low and middle-income countries (LMICs) has markedly increased since 2010, raising challenges to often overstretched and underfunded health care systems. Areas covered: We present an overview of some of these challenges, focusing on programmatic decisions, delivery strategy, information and communication, pharmacovigilance and post-licensure evaluation. We also highlight field-based initiatives that may facilitate NVI. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1574224DOI Listing
February 2019
3 Reads

Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis.

Expert Rev Vaccines 2019 Jan 28:1-14. Epub 2019 Jan 28.

a Sanofi Pasteur , Swiftwater , PA , USA.

Introduction: High-dose trivalent, inactivated, split-virus influenza vaccine (IIV3-HD) has been available in the US since 2009 for adults aged ≥ 65 years. To better understand how IIV3-HD provides improved protection against influenza, we systematically reviewed clinical studies comparing immune responses to IIV3-HD and standard-dose trivalent vaccine (IIV3-SD). Areas covered: The primary objective was to determine the relative hemagglutination inhibition (HAI) antibody response of IIV3-HD vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1575734DOI Listing
January 2019

Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate.

Expert Rev Vaccines 2019 Feb 11;18(2):161-173. Epub 2019 Feb 11.

a Vaccine Department , Center for Genetic Engineering and Biotechnology (CIGB) , Havana , Cuba.

Introduction: Dengue fever remains as a health problem worldwide. Although Dengvaxia®, was registered in several countries, the results after the immunization of people suggest an increase of risk in non-immune persons and children younger than 9 years old. No other vaccine is registered so far, thus the development of a safe and effective vaccine continues to be a priority for the WHO and the scientific community. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1574575DOI Listing
February 2019
4 Reads

Eradication of human papillomavirus and elimination of HPV-related diseases - scientific basis for global public health policies.

Expert Rev Vaccines 2019 Feb 7;18(2):153-160. Epub 2019 Feb 7.

a Department of Laboratory Medicine , Karolinska Institute , Stockholm , Sweden.

Introduction: Infections with oncogenic human papillomaviruses (HPV) globally cause about 9% of cancers in females and 1% of cancers in males. HPV disease burden can be effectively controlled by prophylactic HPV-vaccination provided it has high impact. Areas covered: A unique series of biobank-based and health registry-based studies that exploit randomized intervention cohorts has provided data on population-level safety of HPV vaccination, duration of vaccine-induced protection and impact of gender-neutral HPV vaccination, providing a scientific basis for policies to eradicate oncogenic HPV types and associated diseases worldwide. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1568876DOI Listing
February 2019
5 Reads

Malaria vaccines in the eradication era: current status and future perspectives.

Expert Rev Vaccines 2019 Feb 24;18(2):133-151. Epub 2019 Jan 24.

b School of Health and Biomedical Sciences , RMIT University , Bundoora , Australia.

Introduction: The challenge to eradicate malaria is an enormous task that will not be achieved by current control measures, thus an efficacious and long-lasting malaria vaccine is required. The licensing of RTS, S/AS01 is a step forward in providing some protection, but a malaria vaccine that protects across multiple transmission seasons is still needed. To achieve this, inducing beneficial immune responses while minimising deleterious non-targeted effects will be essential. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1561289DOI Listing
February 2019
1 Read

Measles-vectored vaccine approaches against viral infections: a focus on chikungunya.

Expert Rev Vaccines 2019 Jan 2. Epub 2019 Jan 2.

b Viral Genomics and Vaccination Unit, Department of Virology , Institut Pasteur, CNRS UMR-3965 , Paris , France.

Introduction: The large global burden of viral infections and especially the rapidly spreading vector-borne diseases and other emerging viral diseases show the need for new approaches in vaccine development. Several new vaccine technology platforms have been developed and are under evaluation. Areas covered: This article discusses the measles vector platform technology derived from the safe and highly efficacious measles virus vaccine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1562908DOI Listing
January 2019
2 Reads

Next generation designer virus-like particle vaccines for dengue.

Expert Rev Vaccines 2019 Feb 17;18(2):105-117. Epub 2019 Jan 17.

a Recombinant Gene Products Group, Molecular Medicine Division , International Centre for Genetic Engineering & Biotechnology , New Delhi , India.

Introduction: A safe and efficacious vaccine for dengue continues to be an unmet public health need. The recent licensing of a dengue vaccine (Dengvaxia) developed by Sanofi has brought to the fore the safety issue of vaccine-induced infection enhancement. Areas covered: This article focuses on two new yeast-produced tetravalent dengue envelope domain III-displaying virus-like particulate vaccine candidates reported in early 2018 and reviews the rationale underlying their design, and pre-clinical data which suggest that these may offer promising alternate options. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562909DOI Listing
February 2019
9 Reads

Enhancing uptake of influenza maternal vaccine.

Expert Rev Vaccines 2019 Feb 28;18(2):191-204. Epub 2019 Jan 28.

a Hubert Department of Global Health, Rollins School of Public Health , Emory University , Atlanta , GA , USA.

Introduction: Influenza vaccination during pregnancy can offer many benefits to both mother and infant. Despite recommendations from the Advisory Committee on Immunization Practices, vaccine coverage rates among pregnant women during pregnancy are below 40% in the United States. There is a need for a greater understanding of what interventions can improve vaccine uptake among pregnant women. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562907DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378696PMC
February 2019
16 Reads

Current perspectives in assessing humoral immunity after measles vaccination.

Expert Rev Vaccines 2019 Jan 26;18(1):75-87. Epub 2018 Dec 26.

a Mayo Clinic Vaccine Research Group , Mayo Clinic , Rochester , MN , USA.

Introduction: Repeated measles outbreaks in countries with relatively high vaccine coverage are mainly due to failure to vaccinate and importation; however, cases in immunized individuals exist raising questions about suboptimal measles vaccine-induced humoral immunity and/or waning immunity in a low measles-exposure environment. Areas covered: The plaque reduction neutralization measurement of functional measles-specific antibodies correlates with protection is the gold standard in measles serology, but it does not assess cellular-immune or other parameters that may be associated with durable and/or protective immunity after vaccination. Additional correlates of protection and long-term immunity and new determinants/signatures of vaccine responsiveness such as specific CD46 and IFI44L genetic variants associated with neutralizing antibody titers after measles vaccination are under investigation. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1559063DOI Listing
January 2019
10 Reads

Current landscape of nonmedical vaccination exemptions in the United States: impact of policy changes.

Expert Rev Vaccines 2019 Feb 4;18(2):175-190. Epub 2019 Jan 4.

a Hubert Department of Global Health, Rollins School of Public Health , Emory University , Atlanta , GA , USA.

Introduction: In the United States, high childhood vaccination coverage has reduced the morbidity and mortality due to vaccine-preventable diseases. The success of vaccination programs in achieving this high coverage is due, in part, to vaccination mandates for school entry. All states have such mandates, but there is heterogeneity across the states in the allowance of non-medical exemptions (e. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1562344DOI Listing
February 2019
12 Reads

Accelerating HIV vaccine development using non-human primate models.

Expert Rev Vaccines 2018 Dec 10. Epub 2018 Dec 10.

a Vaccine Branch, Center for Cancer Research , National Cancer Institute, National Institutes of Health , Bethesda , MD.

Introduction: The search for a preventative HIV vaccine is on-going after three decades of research. Contributions of non-human primate (NHP) models to this research are irrefutable, however interpreting data obtained for translation to humans has been problematic. As knowledge concerning NHP models has accumulated, their utility and value in assessing immunogenicity and efficacy of novel vaccines have become apparent. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1557521DOI Listing
December 2018
8 Reads

HPV vaccines and lupus: current approaches towards preventing adverse immune cross-reactivity.

Expert Rev Vaccines 2018 Dec 10. Epub 2018 Dec 10.

c Department of Medicine B and Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan; Sackler Faculty of Medicine , Tel-Aviv University , Tel-Aviv , Israel.

Introduction: If not properly treated, human papillomavirus (HPV) infection may evolve from a common sexually transmitted disease to genital warts and cervical cancer. Various prophylactic HPV vaccines (HPVv), approved to reduce the incidence of the infection, have been found to be effective and safe; however, accounts of post-vaccination autoimmune phenomena, including systemic lupus erythematosus (SLE), have been reported in genetically susceptible individuals. Areas covered: Infectious agents play a role in breaking the immunologic tolerance to self-antigens, resulting in autoimmune events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557519DOI Listing
December 2018
3 Reads

Serotype distribution, antibiotic resistance pattern, and multilocus sequence types of invasive Streptococcus pneumoniae isolates in two tertiary pediatric hospitals in Beijing prior to PCV13 availability.

Expert Rev Vaccines 2019 Jan 12;18(1):89-94. Epub 2018 Dec 12.

a Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases , National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health , Beijing , China.

Background: Invasive pneumococcal disease (IPD) is a serious threat to children worldwide. This study reported the serotype distribution, antibiotic resistance pattern, and multilocus sequence types of 111 IPD strains isolated from children less than 14 years old in two tertiary pediatric centers in Beijing during the years 2012-2017.

Methods: Serotypes were determined using Quellung reaction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557523DOI Listing
January 2019
3 Reads
4.210 Impact Factor

The 5th Virus-like Particle and Nano-Particle Vaccines (VLPNPV) conference.

Expert Rev Vaccines 2018 Dec 10. Epub 2018 Dec 10.

a Department of Rheumatology, Immunology and Allergology , University Hospital Bern, University of Bern , Bern , Switzerland.

Virus-like Particles (VLPs) and Nano-Particles (NPs) are promising vaccine platforms that have led to the successful development of commercially available vaccines. The 5th international Virus-like Particle and Nano-Particle Vaccines (VLPNPV) conference was held in Bern, Switzerland, from the 25th to the 27th of September in 2018. Topics included novel vaccine production techniques, methods to enhance vaccine immunogenicity and preclinical/clinical efficacy evaluation of vaccine candidates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1557522DOI Listing
December 2018
1 Read

Vaccination of healthcare workers: is mandatory vaccination needed?

Expert Rev Vaccines 2018 Dec 1. Epub 2018 Dec 1.

d First Department of Pediatrics , National and Kapodistrian University of Athens , Athens , Greece.

Introduction: Vaccinations of healthcare workers (HCWs) aim to directly protect them from occupational acquisition of vaccine-preventable diseases (VPDs) and to indirectly protect their patients and the essential healthcare infrastructure. However, outbreaks due to VPDs continue to challenge healthcare facilities and HCWs are frequently traced as sources of VPDs to vulnerable patients. In addition, HCWs were disproportionately affected during the current measles outbreak in Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1552141DOI Listing
December 2018
1 Read

Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials.

Authors:
M Arbyn L Xu

Expert Rev Vaccines 2018 Dec 29;17(12):1085-1091. Epub 2018 Nov 29.

a Sciensano , Unit of Cancer Epidemiology/Belgian Cancer Centre , Brussels , Belgium.

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines derived from randomized trials was published in the Cochrane database of Systematic reviews. A summary of this Cochrane review is presented below. Areas covered: Only trials involving mono-, bi-, and quadrivalent HPV vaccines were included. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1548282DOI Listing
December 2018
19 Reads

Current approaches towards identifying a correlate of immune protection from tuberculosis.

Expert Rev Vaccines 2018 Nov 23. Epub 2018 Nov 23.

a Jenner Institute, Nuffield Department of Medicine , University of Oxford , UK.

Introduction: Mycobacterium tuberculosis kills more people than any other pathogen. Vaccination is the most cost-effective control measure for any infectious disease. Development of an effective vaccine against tuberculosis is hindered by the uncertain predictive value of preclinical animal models, incomplete understanding of protective immunity and lack of validated immune correlates of protection (COP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2019.1552140DOI Listing
November 2018
8 Reads

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Expert Rev Vaccines 2018 Dec 5;17(12):1111-1121. Epub 2018 Dec 5.

d Vaccine Development Leader , Research and Development Centre , Rockville , MD , USA.

Introduction: Neisseria meningitidis serogroup B (MenB) is the most common cause of bacterial meningitis in many industrialized countries and occurs at any age. The highest incidence is in infants aged <1 year, followed by children and adolescents. Four-component MenB vaccine (4CMenB, Bexsero) is the only MenB vaccine authorized for use in all age-groups. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1547637DOI Listing
December 2018
26 Reads

Vaccine hesitancy 'outbreaks': using epidemiological modeling of the spread of ideas to understand the effects of vaccine related events on vaccine hesitancy.

Expert Rev Vaccines 2018 Dec 30;17(12):1063-1070. Epub 2018 Nov 30.

a Cochrane South Africa , South African Medical Research Council , Cape Town , South Africa.

Introduction: Vaccine hesitancy, a growing global problem which is aggravated by vaccine related rumors and (mis)information, has the potential to reverse the gains from vaccination. Areas covered: We describe a selection of vaccine-related events that have made headlines and highlight the effects that these have had on vaccine acceptance. Drawing on these cases, and an adaptation of an epidemiological modeling of the spread of ideas, we propose that vaccine hesitancy can be grouped into two categories: 'baseline' and 'reactive' vaccine hesitancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1549994DOI Listing
December 2018
6 Reads

Developing a vaccine for type 1 diabetes by targeting coxsackievirus B.

Expert Rev Vaccines 2018 Dec 29;17(12):1071-1083. Epub 2018 Nov 29.

d Children's Hospital , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.

Introduction: Virus infections have long been considered as a possible cause of type 1 diabetes (T1D). One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started. Areas covered: Epidemiological studies have indicated an association between EVs and T1D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1548281DOI Listing
December 2018
22 Reads

Development of a measure to assess vaccine confidence among men who have sex with men.

Expert Rev Vaccines 2018 11 15;17(11):1053-1061. Epub 2018 Nov 15.

b Rollins School of Public Health, Hubert Department of Global Health , Emory University , Atlanta , GA , USA.

Background: Recent serogroup C meningococcal disease outbreaks led to meningococcal vaccine recommendations for Southern California men who have sex with men (MSM). Assessment of vaccine confidence is critical to improving vaccine coverage in the context of disease outbreaks wherein immunization(s) are recommended.

Methods: We surveyed MSM using venue-based sampling and began development of the vaccine confidence index (VCI) with 30 survey items corresponding to trust- and safety-related perceptions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1541405DOI Listing
November 2018
10 Reads

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?

Expert Rev Vaccines 2018 Dec 15;17(12):1105-1110. Epub 2018 Nov 15.

b Centre for Vaccinology , University Hospitals and University of Geneva , Geneva , Switzerland.

Introduction: The live-attenuated recombinant vesicular stomatitis virus vaccine expressing the glycoprotein (GP) of Zaire Ebola virus (rVSV-ZEBOV) has proven immunogenic in humans and effective in field studies. Yet long-term durability of vaccine responses is unknown. Areas covered: We survey the evidence available in the literature for the durability of human responses to rVSV-ZEBOV. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1546582DOI Listing
December 2018
14 Reads

Effect of HIV exposure and timing of antiretroviral therapy initiation on immune memory responses to diphtheria, tetanus, whole cell pertussis and hepatitis B vaccines.

Expert Rev Vaccines 2018 Nov 10:1-10. Epub 2018 Nov 10.

a Department of Science and Technology, Health Sciences , National Research Foundation:Vaccine Preventable Diseases University of the Witwatersrand , Johannesburg , South Africa.

Objectives: We evaluated memory responses and antibody persistence to diphtheria-toxoid, tetanus-toxoid, whole-cell-pertussis (DTwP), and Hepatitis-B vaccines in HIV-unexposed, HIV-exposed-uninfected and HIV-infected children previously randomized to initiate time-limited ART at 6-10 weeks (ART-Immed) or when clinically/immunologically indicated (ART-Def).

Methods: All children received DTwP booster at 15-18 months. Antibodies were measured for pertussis-toxoid, filamentous haemagglutinin (FHA), diphtheria-toxoid, tetanus-toxoid, and hepatitis-B prior to booster, 1-2 weeks post-booster and at 24 months of age. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2019.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2019.1547195DOI Listing
November 2018
19 Reads

Economic and epidemiological impact of dengue illness over 16 years from a public health system perspective in Brazil to inform future health policies including the adoption of a dengue vaccine.

Expert Rev Vaccines 2018 Dec;17(12):1123-1133

a Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia , Universidade Federal de Minas Gerais , Belo Horizonte , Brazil.

Introduction: Dengue is a serious global health problem endemic in Brazil. Consequently, our aim was to measure the costs and disease burden of symptomatic dengue infections in Brazil from the perspective of the Brazilian Public Health System (SUS) between 2000 and 2015, using Brazilian public health system databases. Specific age group incidence estimates were used to calculate the disability-adjusted life years (DALYs) to gain a better understanding of the disease burden. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1546581DOI Listing
December 2018
15 Reads
4.210 Impact Factor

Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPV-related disease prevention.

Expert Rev Vaccines 2018 Dec 29;17(12):1093-1104. Epub 2018 Nov 29.

a Department of Epidemiology and Biostatistics , Amsterdam UMC, Vrije Universiteit Amsterdam , Amsterdam , Netherlands.

Introduction: Girls-only vaccination against human papillomavirus (HPV) type 16 and 18 was implemented in the Netherlands in 2009. Despite the evidence of the efficacy against precancerous lesions, cross-protection induced by the vaccine and a greater potential for cancer prevention than cervical cancer only, vaccine coverage in the girls-only program has remained below target levels. Areas covered: In this paper, we review the literature from the Netherlands on the effectiveness and cost-effectiveness of HPV vaccination since vaccine introduction, give an account of the coverage, safety and effectiveness of HPV vaccination as has been reported in the Dutch surveillance program and discuss challenges of the current HPV vaccination program. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1547196DOI Listing
December 2018
8 Reads

Case-control study on intestinal intussusception: implications for anti-rotavirus vaccination.

Expert Rev Vaccines 2018 Dec 19;17(12):1135-1141. Epub 2018 Nov 19.

a Department of Science for Health Promotion and Mother-Child Care "G. D'Alessandro" , University of Palermo , Palermo , Italy.

Background: Intussusception represents the most common cause of abdominal emergency among young children but nearly 75% of cases are still considered idiopathic.

Research Design And Methods: A case-control study was conducted among Sicilian children aged 0-59 months with a hospital admission for intussusception between 2009 and 2015 to identify factors associated with intussusception onset.

Results: Overall, 125 cases and 190 controls were recruited for the study. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1546122DOI Listing
December 2018
9 Reads

Basics of CD8 T-cell immune responses after influenza infection and vaccination with inactivated or live attenuated influenza vaccine.

Expert Rev Vaccines 2018 11 15;17(11):977-987. Epub 2018 Nov 15.

a Department of Virology , Federal State Budgetary Scientific Institution "Institute of Experimental Medicine" , Saint Petersburg , Russia.

Introduction: One of the essential mechanisms of virus infection control is cell-mediated cytotoxicity, which can act in an antibody-dependent or -independent fashion and is provided by different effector cells. The role of CD8 T-cells in infection control and in affecting the pathological outcome of different types of infection has been demonstrated in numerous animal studies. Despite this, their role in controlling human influenza infection is not fully understood. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1541407DOI Listing
November 2018
8 Reads

Universal influenza vaccines: from viruses to nanoparticles.

Expert Rev Vaccines 2018 11 2;17(11):967-976. Epub 2018 Nov 2.

a Center for Inflammation, Immunity & Infection , Georgia State University Institute for Biomedical Sciences , Atlanta , GA , USA.

Introduction: The current seasonal influenza vaccine confers only limited protection due to waning antibodies or the antigenic shift and drift of major influenza surface antigens. A universal influenza vaccine which induces broad cross-protection against divergent influenza viruses with a comparable or better efficacy to seasonal influenza vaccines against matched strains will negate the need for an annual update of vaccine strains and protect against possible influenza pandemics. Areas covered: In this review, we summarize the recent progress in nanoparticle-based universal influenza vaccine development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1541408DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300164PMC
November 2018
8 Reads

Post-licensure experience with rotavirus vaccination in Latin America and the Caribbean: a systematic review and meta-analysis.

Expert Rev Vaccines 2018 11 7;17(11):1037-1051. Epub 2018 Nov 7.

c Division of Viral Diseases , Centers for Disease Control and Prevention , Atlanta , GA , USA.

Introduction: Latin American countries were among the first to adopt rotavirus vaccines into national immunization programs; we reviewed one decade of their experience with rotavirus vaccination. Areas covered: We systematically reviewed manuscripts published January 1990-January 2018 to assess rotavirus vaccine effectiveness (VE) via meta-analysis; describe trends in rotavirus and acute gastroenteritis (AGE)-associated hospitalizations and mortality before and after vaccine introduction; and estimate annual hospitalizations and deaths averted by rotavirus vaccination in Latin American and Caribbean children <5 years. Rotavirus vaccines demonstrated VE against rotavirus hospitalization of 76% (95% CI: 58-87) in low-mortality countries and 67% (95% CI: 54-76) in high-mortality countries for children <1 year of age. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1541409DOI Listing
November 2018
13 Reads

Personalized vaccination against ovarian cancer: what are the possibilities?

Expert Rev Vaccines 2018 11 7;17(11):955-958. Epub 2018 Nov 7.

a Department of Obstetrics and Gynecology , University of Pennsylvania Perelman School of Medicine , Philadelphia , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1541743DOI Listing
November 2018
10 Reads

Underlying factors impacting vaccine hesitancy in high income countries: a review of qualitative studies.

Expert Rev Vaccines 2018 11 7;17(11):989-1004. Epub 2018 Nov 7.

d Aix Marseille Univ, IRD, AP-HM, SSA, VITROME , IHU-Méditerranée Infection , Marseille , France.

Introduction: While the scientific consensus on the benefits of vaccination is unambiguous, there is a growing proportion of the population that is skeptical about vaccination. The idea that vaccination programs are losing their momentum concerns public health agencies throughout the world. Many studies assessing determinants of vaccine acceptance have been published in the last decade. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1541406DOI Listing
November 2018
18 Reads

Understanding the role of exogenous boosting in modeling varicella vaccination.

Expert Rev Vaccines 2018 11 5;17(11):1021-1035. Epub 2018 Nov 5.

b Center for Outcomes Research and Real World Evidence , Merck & Co., Inc , Kenilworth , NJ , USA.

Introduction: The exogenous boosting (EB) hypothesis posits that cell-mediated immunity is boosted for individuals reexposed to varicella-zoster virus (VZV). Historically, mathematical models of the impact of universal childhood varicella vaccination (UVV) have used limited data to capture EB and often conclude that UVV will temporarily increase herpes zoster (HZ) incidence. Areas covered: We updated a 2013 systematic literature review of 40 studies to summarize new evidence from observational or modeling studies related to EB and its parameterization. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1538801DOI Listing
November 2018
24 Reads

Life-course immunization as a gateway to health.

Expert Rev Vaccines 2018 10;17(10):851-864

d Department of Translational Research on New Technologies in Medicine and Surgery , University of Pisa , Pisa , Italy.

Introduction: Extending the benefits of vaccination against infectious diseases from childhood throughout the entire life-span is becoming an increasingly urgent priority in view of the world's aging population, emergence and reemergence of infectious diseases, and the necessity to invest more on prevention versus cure in global healthcare. Areas covered: This perspective discusses how life-course immunization could benefit human health at all stages of life. To achieve this, the current vaccination paradigm should be changed and all stakeholders have a role to play. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1527690DOI Listing
October 2018
14 Reads

Poxvirus-based vector systems and the potential for multi-valent and multi-pathogen vaccines.

Expert Rev Vaccines 2018 10 9;17(10):925-934. Epub 2018 Oct 9.

a Inflammation Biology , QIMR Berghofer Medical Research Institute , Brisbane , Australia.

Introduction: With the increasing number of vaccines and vaccine-preventable diseases, the pressure to generate multi-valent and multi-pathogen vaccines grows. Combining individual established vaccines to generate single-shot formulations represents an established path, with significant ensuing public health and cost benefits. Poxvirus-based vector systems have the capacity for large recombinant payloads and have been widely used as platforms for the development of recombinant vaccines encoding multiple antigens, with considerable clinical trials activity and a number of registered and licensed products. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1522255DOI Listing
October 2018
10 Reads

Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned.

Expert Rev Vaccines 2018 11 9;17(11):1005-1020. Epub 2018 Nov 9.

a Catalan Center for HIV Vaccine Research and Development, AIDS Research Unit, Infectious Diseases Department, Hospital Clínic/IDIBAPS, School of Medicine , University of Barcelona , Barcelona , Spain.

Introduction: Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome, tuberculosis, and malaria are responsible for most human deaths produced by infectious diseases worldwide. Vaccination against HIV requires generation of memory T cells and neutralizing antibodies, mucosal immunity, and stimulation of an innate immune responses. In this context, the use of Mycobacterium bovis bacillus Calmette-Guérin (BCG) as a live vaccine vehicle is a promising approach for T-cell induction. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1534588DOI Listing
November 2018
15 Reads

Applying lessons from human papillomavirus vaccines to the development of vaccines against Chlamydia trachomatis.

Expert Rev Vaccines 2018 11 20;17(11):959-966. Epub 2018 Oct 20.

a Department of Molecular Genetics and Microbiology , School of Medicine, University of New Mexico , Albuquerque , NM , USA.

Introduction: Chlamydia trachomatis (Ct), the most common bacterial sexually transmitted infection (STI), leads to pelvic inflammatory disease, infertility, and ectopic pregnancy in women. In this Perspective, we discuss the successful human papillomavirus (HPV) vaccine as a case study to inform Ct vaccine efforts. Areas covered: The immunological basis of HPV vaccine-elicited protection is high-titer, long-lasting antibody responses in the genital tract which provides sterilizing immunity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1534587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246778PMC
November 2018
5 Reads

Unprecedented pace and partnerships: the story of and lessons learned from one Ebola vaccine program.

Expert Rev Vaccines 2018 10 12;17(10):913-923. Epub 2018 Oct 12.

a Global Clinical Development , Merck & Co., Inc , Kenilworth , NJ , USA.

Introduction: The Ebola epidemic in West Africa from 2014 to 2016 was unique in its size, location, and duration; this article reviews the experiences and lessons learned for one vaccine candidate developed during the outbreak and discusses critical gaps that still exist today which will need to be addressed for successful end to end emerging infectious disease vaccine product development in the future. Areas Covered: Through the formation of numerous international partnerships, the rVSVΔG-ZEBOV-GP vaccine advanced through Phase I/II/III clinical trials which resulted in favorable Phase III efficacy results. Key lessons learned that could be used to facilitate future vaccine development efforts include sufficient preclinical work in relevant animal models, innovative partnerships created to pool resources and expertise, and 'hyper' coordination and communication among partners to build trust and ensure an adequate regulatory package needed to license a vaccine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14760584.2018.1527692DOI Listing
October 2018
10 Reads

Influenza vaccination and prevention of antimicrobial resistance.

Expert Rev Vaccines 2018 10 12;17(10):881-888. Epub 2018 Oct 12.

b Università degli Studi di Milano , Milan , Italy.

Introduction: Abuse and misuse of available antimicrobial drugs have increased antimicrobial resistance (AMR), with relevant adverse health and economic impacts. Several factors suggest that the influenza vaccine is a possible effective measure to control AMR through a significant reduction in antibiotic consumption. In this paper, aspects related will be discussed. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14760584.2018.1
Publisher Site
http://dx.doi.org/10.1080/14760584.2018.1525298DOI Listing
October 2018
3 Reads